pING-HER3 Vaccine for Cancer

What is the Purpose of this Study?

We are doing this study to find out how an experimental vaccine (pING-hHER3FL) works in your body and against your cancer.

What is the Condition Being Studied?

Cancer

Who Can Participate in the Study?

People who:

  • Have the one of the following cancers:
    • Breast
    • Colon
    • Lung
    • Prostate
    • Ovarian
    • Cervical
    • Endometrial
    • Gastric (stomach)
    • Pancreatic
    • Bladder
    • Head and neck
    • Liver
    • Esophageal
  • Have been treated with surgery and/or chemotherapy and radiation

For more information about who can join this study, please contact the study team at felecia.walton@duke.edu.

Age Group
Adults

What is Involved?

If you choose to do this study, you will:

  • Get the study vaccine three times over 8 weeks
  • Have occasional blood draws for 5 years
  • Have a biopsy to collect tumor tissue, if necessary

Study Details

Full Title
ASSESSING THE IMMUNOGENICITY OF pING-hHER3FL VACCINE IN PATIENTS WITH RESECTED MALIGNANCIES
Principal Investigator
Headshot of Michael Aaron Morse
Professor of Medicine
Protocol Number
IRB: PRO00104093
NCT: NCT03832855
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate